Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Mikhael

Showing results (51-60 of 104) with videos related to

Pageof 11
Sort By:
Therapeutic Advances in Hematology|April 8, 2022
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairmentMeletios A Dimopoulos, Joseph Mikhael, Evangelos Terpos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2011
Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survivalVictor H Jimenez-Zepeda, Joseph Mikhael, Andrew Winter, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2023
Heart Failure Among Patients with Multiple Myeloma Treated with Carfilzomib-Based Versus Non-Carfilzomib-Based Regimens in the United States by RaceShuling Li, Brandon T Suehs, Alan Fu, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 3, 2023
Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial DisparitiesJoseph Mikhael, Allie Cichewicz, Elizabeth S Mearns, et al.
Hematological Oncology|February 16, 2018
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trialsMaria-Victoria Mateos, Hartmut Goldschmidt, Jesus San-Miguel, et al.
Blood Cancer Journal|March 13, 2021
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myelomaPaul G Richardson, Thierry Facon, William I Bensinger, et al.
Cancer Medicine|February 3, 2015
Quality of life and disease understanding: impact of attending a patient-centered cancer symposiumLeslie Padrnos, Amylou C Dueck, Robyn Scherber, et al.
Blood|March 14, 2019
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myelomaJoseph Mikhael, Paul Richardson, Saad Z Usmani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 29, 2014
Financial burden in recipients of allogeneic hematopoietic cell transplantationNandita Khera, Yu-hui Chang, Shahrukh Hashmi, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2020
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With SelinexorJoseph Mikhael, Kimberly R Noonan, Beth Faiman, et al.
Pageof 11

Showing results (51-60 of 104) with videos related to

Sort By:
Pageof 11
Therapeutic Advances in Hematology|April 8, 2022
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairmentMeletios A Dimopoulos, Joseph Mikhael, Evangelos Terpos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2011
Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survivalVictor H Jimenez-Zepeda, Joseph Mikhael, Andrew Winter, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2023
Heart Failure Among Patients with Multiple Myeloma Treated with Carfilzomib-Based Versus Non-Carfilzomib-Based Regimens in the United States by RaceShuling Li, Brandon T Suehs, Alan Fu, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 3, 2023
Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial DisparitiesJoseph Mikhael, Allie Cichewicz, Elizabeth S Mearns, et al.
Hematological Oncology|February 16, 2018
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trialsMaria-Victoria Mateos, Hartmut Goldschmidt, Jesus San-Miguel, et al.
Blood Cancer Journal|March 13, 2021
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myelomaPaul G Richardson, Thierry Facon, William I Bensinger, et al.
Cancer Medicine|February 3, 2015
Quality of life and disease understanding: impact of attending a patient-centered cancer symposiumLeslie Padrnos, Amylou C Dueck, Robyn Scherber, et al.
Blood|March 14, 2019
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myelomaJoseph Mikhael, Paul Richardson, Saad Z Usmani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 29, 2014
Financial burden in recipients of allogeneic hematopoietic cell transplantationNandita Khera, Yu-hui Chang, Shahrukh Hashmi, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2020
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With SelinexorJoseph Mikhael, Kimberly R Noonan, Beth Faiman, et al.
Pageof 11